Skip to content
Roxadustat
Evrenzo (roxadustat) is a small molecule pharmaceutical. Roxadustat was first approved as Evrenzo on 2021-08-18. It has been approved in Europe to treat anemia and chronic kidney failure.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B03: Antianemic preparations
— B03X: Other antianemic preparations in atc
— B03XA: Other antianemic preparations in atc
— B03XA05: Roxadustat
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N181592118
AnemiaD000740EFO_0004272D64.91781—17
Heart failureD006333EFO_0003144I50———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.6—32——5
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DialysisD003956—1———1
St elevation myocardial infarctionD000072657—1———1
Coronary artery bypassD001026EFO_0003776—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—9————9
Hepatic insufficiencyD0485501————1
Renal insufficiencyD051437HP_0000083N191————1
Renal dialysisD006435EFO_0010690Z99.21————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardio-renal syndromeD059347————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameROXADUSTAT
INNroxadustat
Description
Roxadustat is an N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH). It has a role as an EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor and an EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor. It is a member of isoquinolines, an aromatic ether and a N-acylglycine.
Classification
Small molecule
Drug classenzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12
Identifiers
PDB—
CAS-ID808118-40-3
RxCUI—
ChEMBL IDCHEMBL2338329
ChEBI ID—
PubChem CID11256664
DrugBankDB04847
UNII IDX3O30D9YMX (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Roxadustat - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 816 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
38 adverse events reported
View more details